gil-c-shutterstock-com-4-1-merck

Gil C / Shutterstock.com

16 December 2016Americas

Merck subsidiary awarded $2.5bn in patent case against Gilead

Idenix Pharmaceuticals, a subsidiary of Merck, has been awarded $2.5 billion in a patent battle against Gilead over Gilead's drugs Sovaldi (sofosbuvir) and Harvoni (ledipasvir/sofosbuvir), treatments for hepatitis C.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More features

Gilead awarded $30m over counterfeit HIV drug scheme

EPO invalidates human milk patent after Nestle opposition

Bayer gains exclusive licence for heart drug in Japan

EPO delivers key Novo Nordisk, GSK and Inhibrx rulings

McGuireWoods expands team with ex-Novo Nordisk GC

Paul, Weiss swoops for senior duo from Weil, Gotshal

UPC bans Meril Life Sciences from selling infringing heart valve

SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic